
TEVA-SPONSORED VIRTUAL SATELLITE SYMPOSIUM AT THE 7TH CONGRESS OF THE EUROPEAN ACADEMY OF NEUROLOGY

Current and future approaches to migraine prevention

20 JUN 13:45-14:45 CEST JOIN ONLINE



Current and future approaches to migraine prevention

WELCOME

Dear colleagues,

With great pleasure, I invite you to join us at this Teva-sponsored satellite symposium, taking place during the virtual 7th Congress of the European Academy of Neurology (EAN).

Efficacy and safety data from clinical trials of monoclonal antibodies targeting the CGRP pathway (anti-CGRP mAbs) have supported their adoption in practice; however, several questions remain surrounding treatment goals, long-term use and other clinical considerations.

During this virtual symposium, we will discuss preventive treatment outcomes beyond a reduction in migraine or headache days and provide an update on some of the latest long-term data relating to anti-CGRP mAbs, including patient dosing preferences. Looking to the future, we will also consider ongoing real-world studies and how emerging data from these may help to answer outstanding questions, such as starting and stopping rules and switching.

I hope you will join us for what promises to be an engaging and informative symposium.

Katieser

Zaza Katsarava, Chair Christian Hospital Unna and University of Duisberg-Essen Essen, Germany



To register for the virtual EAN congress, please visit <u>www.ean.org/congress-2021/discover/register</u>. The symposium will include the opportunity to ask questions to the faculty throughout the presentations.

PROGRAMME



Welcome

Zaza Katsarava, Germany (Chair)



Rethinking preventive treatment goals in the CGRP era

Hans-Christoph Diener, Germany



Long-term use of anti-CGRP mAbs: what do we know?

Dagny Holle-Lee, Germany



Looking to the future: what can we expect next from anti-CGRP mAbs?

Piero Barbanti, Italy



Panel discussion and closing remarks Facilitated by Zaza Katsarava

